Predictive Oncology Inc. (POAI): Price and Financial Metrics

Predictive Oncology Inc. (POAI): $0.36

-0.01 (-1.78%)

POWR Rating

Component Grades













Add POAI to Watchlist
Sign Up

Industry: Biotech



in industry

POAI Stock Summary

  • The ratio of debt to operating expenses for PREDICTIVE ONCOLOGY INC is higher than it is for about only 5.02% of US stocks.
  • With a price/sales ratio of 18, PREDICTIVE ONCOLOGY INC has a higher such ratio than 93.95% of stocks in our set.
  • With a year-over-year growth in debt of -78.04%, PREDICTIVE ONCOLOGY INC's debt growth rate surpasses just 2.46% of about US stocks.
  • Stocks that are quantitatively similar to POAI, based on their financial statements, market capitalization, and price volatility, are GHSI, UNAM, AAN, WYY, and YCBD.
  • POAI's SEC filings can be seen here. And to visit PREDICTIVE ONCOLOGY INC's official web site, go to

POAI Valuation Summary

  • In comparison to the median Healthcare stock, POAI's EV/EBIT ratio is 100% lower, now standing at 0.
  • Over the past 153 months, POAI's EV/EBIT ratio has gone up 1.5.

Below are key valuation metrics over time for POAI.

Stock Date P/S P/B P/E EV/EBIT
POAI 2022-11-25 15.8 0.9 -1.0 0.0
POAI 2022-11-23 15.2 0.8 -1.0 0.0
POAI 2022-11-22 15.0 0.8 -0.9 0.0
POAI 2022-11-21 14.3 0.8 -0.9 0.1
POAI 2022-11-18 14.6 0.8 -0.9 0.1
POAI 2022-11-17 14.0 0.8 -0.9 0.1

POAI Growth Metrics

    Its 3 year price growth rate is now at -89.31%.
  • Its 2 year net income to common stockholders growth rate is now at 8.5%.
  • Its 4 year cash and equivalents growth rate is now at 63.95%.
POAI's revenue has moved up $242,844 over the prior 37 months.

The table below shows POAI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.618479 -12.87992 -25.57803
2022-06-30 1.476315 -13.10976 -26.95657
2022-03-31 1.454931 -11.98053 -19.13918
2021-12-31 1.42068 -12.20893 -19.65717
2021-09-30 1.237975 -10.76877 -23.37064
2021-06-30 1.405069 -11.06363 -24.79463

POAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • POAI has a Quality Grade of D, ranking ahead of 8.37% of graded US stocks.
  • POAI's asset turnover comes in at 0.042 -- ranking 162nd of 186 Medical Equipment stocks.
  • INO, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with POAI.

The table below shows POAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 0.637 -7.254
2021-03-31 0.047 0.635 -18.054
2020-12-31 0.055 0.643 58.433
2020-09-30 0.052 0.629 16.113
2020-06-30 0.050 0.616 9.041
2020-03-31 0.052 0.621 9.870

POAI Price Target

For more insight on analysts targets of POAI, see our POAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

POAI Stock Price Chart Interactive Chart >

Price chart for POAI

POAI Price/Volume Stats

Current price $0.36 52-week high $1.10
Prev. close $0.37 52-week low $0.21
Day low $0.35 Volume 263,300
Day high $0.36 Avg. volume 536,237
50-day MA $0.31 Dividend yield N/A
200-day MA $0.52 Market Cap 28.61M

Predictive Oncology Inc. (POAI) Company Bio

Predictive Oncology Inc. operates as a biotechnology company. The Company focuses focuses on applying data and artificial intelligence to personalized medicine and drug discovery. Predictive Oncology serves customers worldwide.

POAI Latest News Stream

Event/Time News Detail
Loading, please wait...

POAI Latest Social Stream

Loading social stream, please wait...

View Full POAI Social Stream

Latest POAI News From Around the Web

Below are the latest news stories about PREDICTIVE ONCOLOGY INC that investors may wish to consider to help them evaluate POAI as an investment opportunity.

Analysts Are Bullish on Top Healthcare Stocks: Galectin Therapeutics (GALT), Viridian Therapeutics (VRDN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Galectin Therapeutics (GALT – Research Report), Viridian Therapeutics (VRDN – Research Report) and Predictive Oncology (POAI – Research Report) with bullish sentiments. Galectin Therapeutics (GALT) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics today and set a price target of $11.00. The company's shares closed last Monday at $1.29, close to its 52-week low of $1.13. According to TipRanks.

Christine Brown on TipRanks | November 15, 2022

Predictive Oncology Reports Third Quarter Financial Results

EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include: Raymond F. Vennare, has been appointed as Chief Executive Officer and Chairman of the Board. An accomplished executive with more than three decades of experience, Mr. Vennare has

Yahoo | November 10, 2022

David S. Smith appointed to the Board of Directors of Predictive Oncology

Leading authority on the therapeutic use of human tissues and cells Director, Predictive Oncology Inc. David S. Smith, JD EAGAN, Minn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. He has

Yahoo | October 25, 2022

AI cancer-therapy firm Predictive Oncology names experienced biotech exec as its next CEO

Eagan-based Predictive Oncology, a company that uses AI to enable the development of cancer therapies, has named a new CEO.

Yahoo | October 21, 2022

Predictive Oncology Inc. (NASDAQ:POAI) stock crossing the finish line today

Predictive Oncology Inc. (POAI)’s stock has witnessed a price hike of 2.96% from the previous close with its current price standing at $0.29. Its current price is -77.85% under its 52-week high of $1.33 and 18.08% more than its 52-week low of $0.25. Based on the past 30-day period, the stock price is -30.21% below […]

US Post News | October 20, 2022

Read More 'POAI' Stories Here

POAI Price Returns

1-mo 32.11%
3-mo -10.00%
6-mo -21.74%
1-year -65.05%
3-year -88.35%
5-year -97.25%
YTD -62.18%
2021 29.97%
2020 -71.94%
2019 -57.90%
2018 -38.61%
2017 -63.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8075 seconds.